

Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007–2010

Matteo Zignol,^a Wayne van Gemert,^a Dennis Falzon,^a Charalambos Sismanidis,^a Philippe Glaziou,^a Katherine Floyd^a & Mario Raviglione^a

Objective To present a global update of drug-resistant tuberculosis (TB) and explore trends in 1994–2010.

Methods Data on drug resistance among new and previously treated TB patients, as reported by countries to the World Health Organization, were analysed. Such data are collected through surveys of a representative sample of TB patients or surveillance systems based on routine drug susceptibility testing. Associations between multidrug-resistant TB (MDR-TB) and human immunodeficiency virus (HIV) infection and sex were explored through logistic regression.

Findings In 2007–2010, 80 countries and 8 territories reported surveillance data. MDR-TB among new and previously treated cases was highest in the Russian Federation (Murmansk oblast, 28.9%) and the Republic of Moldova (65.1%), respectively. In three former Soviet Union countries and South Africa, more than 10% of the cases of MDR-TB were extensively drug-resistant. Globally, in 1994 to 2010 multidrug resistance was observed in 3.4% (95% confidence interval, CI: 1.9–5.0) of all new TB cases and in 19.8% (95% CI: 14.4–25.1) of previously treated TB cases. No overall associations between MDR-TB and HIV infection (odds ratio, OR: 1.4; 95% CI: 0.7–3.0) or sex (OR: 1.1; 95% CI: 0.8–1.4) were found. Between 1994 and 2010, MDR-TB rates in the general population increased in Botswana, Peru, the Republic of Korea and declined in Estonia, Latvia and the United States of America.

Conclusion The highest global rates of MDR-TB ever reported were documented in 2009 and 2010. Trends in MDR-TB are still unclear in most settings. Better surveillance or survey data are required, especially from Africa and India.

Abstracts in **عربي**, **中文**, **Français**, **Русский** and **Español** at the end of each article.

Introduction

Surveillance of resistance to drugs against tuberculosis (TB) is a cornerstone of any TB control programme. Surveillance data on drug resistance are needed to track the effectiveness of TB prevention and control activities; accurately forecast the need for patient treatments and plan accordingly; design standardized regimens for the treatment of drug-resistant TB; assess epidemiological trends; and promptly identify and respond to outbreaks of drug-resistant TB.¹ Since 1994 the Global Project on Anti-Tuberculosis Drug Resistance Surveillance of the World Health Organization (WHO) has supported national TB control programmes worldwide in implementing drug resistance surveillance activities. Country data are routinely collected, analysed and disseminated to describe the global problem of drug-resistant TB.^{2–11}

Patients whose mycobacteria are resistant to rifampicin, isoniazid and other anti-TB drugs require longer, expensive and more toxic treatment regimens and are less likely to be cured. This presents a formidable challenge to programmes, particularly in low-resource settings.¹² Policy guidance on the programmatic management of drug-resistant TB^{13–15} and on how to control the transmission of resistant strains¹⁶ has been developed by WHO, and access to quality-assured second-line anti-TB drugs for the treatment of multidrug-resistant TB (MDR-TB) is facilitated through the Green Light Committee mechanism.¹⁷ The number of TB patients diagnosed and treated for MDR-TB, which is defined as TB caused by strains of *Mycobacterium tuberculosis* that are resistant to at least isoniazid and rifampicin,¹³ is increasing worldwide, but much remains to be done. In 2010, only 16% of the TB patients estimated to have MDR-TB were diagnosed and given appropriate

treatment.^{11,12} Routine surveillance of drug resistance must be linked to patient care.

Over the past three years, WHO has been actively encouraging countries to establish continuous TB drug resistance surveillance systems based on routine drug susceptibility testing of all patients, with priority given to patients previously treated, who are at highest risk of developing drug resistance.^{18–20} Although limited laboratory capacity for drug susceptibility testing still represents a major obstacle to the establishment of surveillance systems in low-resource settings, new diagnostic tools such as line probe assays²¹ and Xpert MTB/RIF,²² combined with greater resources for laboratory strengthening, offer an unprecedented opportunity to scale up surveillance systems worldwide.

In this paper we evaluate the existing information on anti-TB drug resistance surveillance, with an emphasis on data reported in 2007–2010, after the publication of WHO's fourth global report on anti-TB drug resistance surveillance.^{8,9} We present a global overview of the extent of the problem of MDR-TB, explore associations between MDR-TB and human immunodeficiency virus (HIV) infection and sex, discuss time trends in drug resistance, and present available data on extensively drug-resistant TB (XDR-TB) – the latter defined as MDR-TB plus resistance to a fluoroquinolone and at least one second-line injectable agent (amikacin, kanamycin or capreomycin).¹³

Methods

Definitions and data collection

Drug resistance surveillance data are gathered following three main principles: (i) the data are representative of TB cases

^a STOP TB Department, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland.

Correspondence to Matteo Zignol (e-mail: zignolm@who.int).

(Submitted: 24 June 2011 – Revised version received: 7 October 2011 – Accepted: 10 October 2011 – Published online: 7 November 2011)

in the country or geographical setting under study; (ii) drug resistance among new TB cases is examined separately from drug resistance among previously treated TB cases; and (iii) laboratory methods for drug susceptibility testing are selected from among those that are recommended by WHO, with quality assurance for all laboratory processes conducted in cooperation with a partner supranational reference laboratory from the global network of 29 such laboratories.^{18,19,23,24}

Drug resistance surveillance data are collected separately for new (previously untreated) and previously treated TB cases²⁵ via special surveys or continuous surveillance. Special surveys measure drug resistance among a representative sample of notified cases of smear-positive pulmonary TB; continuous surveillance systems are based on routine diagnostic drug susceptibility testing in all bacteriologically-confirmed TB patients. Aggregated data from special surveys are collected through a standard data collection form, whereas continuous surveillance data are captured through “WHO[’s] global TB data collection system”.²⁶ WHO ascertains whether survey and continuous surveillance data meet quality and representativeness standards through criteria detailed elsewhere.¹⁰ The main indicator reported to estimate the frequency of MDR-TB is the proportion of confirmed TB cases with resistance to rifampicin and isoniazid. Data on resistance to any fluoroquinolone and second-line injectable agent among confirmed cases of MDR-TB are used to estimate the frequency of XDR-TB.

Data description, analysis and trends

The proportions of new and previously treated TB cases with MDR-TB and the proportion of MDR-TB cases with XDR-TB were calculated using the latest available national and subnational data. To derive global estimates for these indicators and to investigate the association between MDR-TB and HIV infection and sex, individual-level analyses were conducted using random-effects or robust standard errors logistic regression models to account for the clustering effect at the level of a country or territory. We used the I^2 index²⁷ to assess heterogeneity in country-level odds ratios (OR) before we combined these to obtain a pooled estimate. STATA ver-

sion 11 (StataCorp. LP, College Station, United States of America) was used for all analyses.

Time trends in MDR-TB rates (annual number of new cases per 100 000 population)²⁸ between 1994 and 2010 were calculated by multiplying the new TB case notification rates reported annually to WHO¹¹ by the reported frequency of MDR-TB among new TB cases in the same setting and year. Exponential lines were fitted and the annual percentage change in the rate of MDR-TB was calculated for settings where anti-TB drug resistance had been measured in at least three different years.

Results

Since the launch of the Global Project on Anti-tuberculosis Drug Resistance Surveillance in 1994, drug resistance data have been systematically collected and analysed from 127 countries, or 66% of WHO’s 193 Member States. This includes 64 countries that have continuous surveillance systems based on routine diagnostic drug susceptibility testing of all patients. The remaining 63 countries have relied on special surveys of representative samples of patients. Of the 127 countries with surveillance information, 56 have data from one year only, 20 from two years, and 51 from three or more years (Fig. 1).

Most recent data, 2007–2010

Between 2007 and 2010, resistance to first-line anti-TB drugs was reported from 80 countries and 8 territories, 72 of which provided data from continuous surveillance and 16 from special surveys (Table 1, available at: <http://www.who.int/bulletin/volumes/90/2/11-092585>). Almost all countries (82/88, or 93%) reported nationwide data. Bangladesh (14 districts covering a population of 30 million), the Plurinational State of Bolivia, Chile, Colombia, El Salvador, Fiji, Kazakhstan, Lebanon, Mongolia, the Republic of Moldova, Rwanda and Sri Lanka provided continuous surveillance data on previously treated but not new TB cases. Subnational data were reported from Bangladesh, the Central African Republic, Indonesia, the Russian Federation (12 oblasts [administrative regions] and republics), Tajikistan and Uganda.

The proportion of new TB cases reported as showing multidrug resistance in these years ranged from 0%

to 28.9%. Proportions exceeding 12% (in countries reporting more than 10 MDR-TB cases) were documented in Belarus (25.7%), Estonia (18.3%), several oblasts of the Russian Federation (with Murmansk having the highest level, 28.9%) and Tajikistan (Dushanbe city and Rudaki district, 16.5%).

The proportion of previously treated cases having MDR-TB ranged from 0% to 65.1%. Countries or subnational areas with proportions exceeding 50% included Belarus (60.2%), Lithuania (51.5%), the Republic of Moldova (65.1%), five oblasts of the Russian Federation, and Tajikistan (Dushanbe city and Rudaki district, 61.6%) (Table 1).

The largest country that conducted a nationwide survey in the reporting period was China, where 5.7% of new TB cases and 25.6% of previously treated cases were found to have multidrug resistance (Table 1).

Surveillance data on XDR-TB were reported from 38 countries and 3 territories, 34 of which routinely test all patients with MDR-TB for second-line anti-TB drug resistance. Only 6 out of 41 (15%) countries and territories reported more than 10 cases of XDR-TB; the proportion of MDR-TB cases that were extensively drug-resistant exceeded 10% in Estonia (19.7%), Latvia (15.1%), South Africa (10.5%) and Tajikistan (Dushanbe city and Rudaki district, 21.0%) (Table 2, available at: <http://www.who.int/bulletin/volumes/90/2/11-092585>).

Overall data, 1994–2010

The proportions of new and previously treated TB cases in the world that were multidrug resistant are shown in Fig. 2 and Fig. 3, respectively. Overall, when data from all countries and territories were combined, the global proportions of new and previously treated TB cases showing multidrug resistance were 3.4% (95% CI: 1.9–5.0) and 19.8% (95% CI: 14.4–25.1), respectively. Regional level estimates of the proportion of cases with MDR-TB are shown in Table 3.

XDR-TB has been identified in 77 countries globally, and 57 countries and 3 territories were able to report representative data from continuous surveillance or special surveys on the proportion of XDR-TB cases among MDR-TB cases. Combined data from all countries and territories showed that the proportion of MDR-TB cases with extensive drug resistance was 9.4% (95% CI: 7.4–11.6).

Fig. 1. Number of country–year data points for drug resistance surveillance, 1994–2010






Fig. 2. Distribution of percentage of new tuberculosis cases with multidrug-resistant tuberculosis (MDR-TB)



Note: Showing latest available data, 1994–2010. Reported data for the Democratic Republic of the Congo, Luxembourg, New Caledonia and the Solomon Islands are not disaggregated by new and previously treated tuberculosis cases and are therefore not shown.

Fig. 3. Percentage of previously treated tuberculosis patients with multidrug-resistant tuberculosis (MDR-TB)



Note: Showing latest available data, 1994–2010. Reported data for the Democratic Republic of the Congo, Luxembourg, New Caledonia and the Solomon Islands are not disaggregated by new and previously treated tuberculosis cases and are therefore not shown.

Table 3. Average proportions of cases of tuberculosis, new or previously treated, that are multidrug-resistant in regions of the World Health Organization (WHO) and the world, 1994–2000

WHO region	New cases		Previously treated cases	
	%	95% CI	%	95% CI
African region	1.9	0.6–3.3	9.4	3.0–15.8
Region of the Americas	2.1	0.7–3.4	11.5	3.8–19.2
Eastern Mediterranean region	3.4	0.9–5.9	20.6	7.5–33.7
European region ^a	12.1	8.6–15.6	36.5	32.5–40.6
South-East Asia region	2.1	1.7–2.5	17.2	16.5–17.7
Western Pacific region	4.9	3.6–6.1	23.2	19.6–26.9
World	3.4	1.9–5.0	19.8	14.4–25.1

CI, confidence interval.

^a The values for Europe reflect the high levels of multidrug resistance documented in eastern European countries: 14.3% (95% CI: 12–16.7) among new cases and 39% (95% CI: 35.1–42.9) among previously treated cases of tuberculosis.

Note: The data were obtained from the World Health Organization.^{10,11}

Risk factors


When data from 17 countries and 1 territory that reported drug resistance data stratified by HIV status were combined, the odds of having MDR-TB among HIV-positive cases were found to be 40% higher than among HIV-negative cases (pooled odds ratio, OR: 1.4; 95% CI: 0.7–3.0; OR consistent across countries, $I^2 = 23.2%$; P -value = 0.19), but the difference was not significant. Thus, no association was noted between the presence of MDR-TB and HIV status.

A total of 58 countries and 2 special territories reported drug resistance surveillance data disaggregated by sex. Overall, when data from these settings were combined, the odds of having MDR-TB were found to be 10% higher among females than males (OR: 1.1; 95% CI: 0.8–1.4; OR heterogeneous across countries, $I^2 = 32.9%$; P -value = 0.009), but the difference was not significant. Thus, no association was noted between the presence of MDR-TB and the sex of the patient.

Time trends

Data on time trends in drug resistance were available from 71 countries and 751 country-year data points. Selected data to illustrate the diversity of trends in TB and MDR-TB worldwide are presented in Fig. 4. In a first group of countries, composed of Botswana, Peru and the Republic of Korea, the estimated notification rate of MDR-TB is increasing (+10.9%, +19.4% and +4.3% per year, respectively). In these countries, trends in notifications of new TB cases vary, with a clear increase in the Republic of Korea (+7.4% per year), a rather stable trend in Botswana (+0.3% per year) and a clear decline in Peru (–3.3% per year). A second group is composed of three Russian oblasts where TB notification rates are stable or decreasing. Although in these oblasts MDR-TB rates were on the rise until around 2005–2006, they have subsequently been falling in all three settings. In a third group of countries, composed of Estonia, Latvia and the United States, surveillance data suggest that both TB and MDR-TB rates have been falling for more than a decade. In the United States the rate of MDR-TB is falling even more quickly than the TB case notification rate.

Fig. 4. Time trends in population rates of new cases of tuberculosis (TB) and new cases of multidrug-resistant tuberculosis (MDR-TB)



Note: Data are for new TB cases, except for those of the United States of America, whose data are for combined new and previously treated TB cases.

Discussion

In 2007–2010, several countries provided drug resistance surveillance data generated from continuous surveillance systems rather than special surveys, a change from previous reports.^{8,9} Of particular interest is a group of 12 countries that have succeeded in establishing continuous surveillance systems for previously treated TB cases: Bangladesh (14 districts covering a population of 30 million), the Plurinational State of Bolivia, Chile, Colombia, El Salvador, Fiji, Kazakhstan, Lebanon, Mongolia, the Republic of Moldova, Rwanda and Sri Lanka. This is the first step towards routine drug susceptibility testing for all TB cases and allows early identification of drug resistance in the population at greatest risk.^{18–20}

Available data confirm that eastern Europe and central Asia continue to have the world’s highest proportion of MDR-TB among TB cases. In 2007–2010 the highest proportions ever reported globally were documented in areas of the former Soviet Union; MDR-TB was reported among nearly 30% of new TB cases in the oblast of Murmansk in the Russian Federation and among 65% of previously treated TB cases in the Republic of Moldova. In a few other oblasts of the Russian Federation in the same region, levels of MDR-TB appear to be stabilizing or even decreasing, which confirms that addressing MDR-TB is feasible even in high-burden areas. Unfortunately, large parts of eastern Europe and central Asia still lack representative data. This applies to the whole of Kyrgyzstan and most of Azerbaijan,

the Russian Federation, Tajikistan, Turkmenistan, Ukraine and Uzbekistan. With planned and ongoing surveys and improvements in continuous surveillance in these countries, major strides towards improving our understanding of the true burden of drug-resistant TB are expected in the near future.

China conducted its first nationwide survey in 2007. The survey, which confirmed previously published estimates^{8,9} based on extrapolation from subnational level data, represents a critical step towards addressing MDR-TB in one of the largest TB control programmes in the world. Whereas China has been able to conduct a nationwide survey, India and the Russian Federation – the other two large countries that, with China, contribute to more than 50% of the estimated global burden of MDR-TB

– have only produced reliable subnational level data to date. To understand the magnitude of the MDR-TB problem and address it, nationwide surveillance systems should be established in all countries, with greater urgency in the highest burden settings.

Only 34 countries and settings have a system in place to routinely test all patients with MDR-TB for second-line anti-TB drug resistance. These are generally countries with established or emerging economies, as laboratory capacity for second-line drug susceptibility testing in resource-limited settings is still scarce.

The average proportions of MDR-TB cases among diagnosed TB cases detected in this study are consistent with previous reports.^{8,9} The lack of data on drug-resistant TB in most African countries is still a matter of major concern (Fig. 2 and Fig. 3). This situation should be urgently addressed, especially since the African Region accounts for over 80% of the TB cases among people living with HIV and since higher mortality from MDR-TB and XDR-TB has been documented in HIV-positive patients.²⁹ The availability of new molecular technologies for diagnosing TB and detecting rifampicin resistance, including line probe assays and Xpert MTB/RIF, represent an unprecedented opportunity for countries with severely limited laboratory infrastructure to diagnose drug resistance more easily. Line probe assays permit safer transportation of specimens, require a lower workload than conventional culture and drug susceptibility tests, and reduce to two days the time needed for the diagnosis of MDR-TB.^{30,31} Xpert MTB/RIF is an automated nucleic acid amplification technology that detects rifampicin resistance in less than two hours. It is very simple to use and requires limited training and biosafety measures.²² A few countries have piloted the use of molecular technologies in drug resistance surveys,^{30,31} but data from surveys using exclusively those techniques are not yet available. Molecular technologies are expected to contribute substantially to surveillance of drug-resistant TB in low-resource settings in the future.

The analysis of risk factors for MDR-TB showed that the overall risk of harbouring MDR-TB strains is not influenced by sex. The sex distribution of patients with MDR-TB does not differ from that of patients with drug-susceptible TB. This finding is not surprising, since MDR-TB is a form of TB and has similar risk factors. Countries where an association is documented should be investigating the possible reasons.

Although an association between HIV infection and MDR-TB has been widely documented in hospital outbreaks of drug-resistant TB among people living with HIV,^{32–34} the population-based data gathered to date suggest that the relationship between multidrug resistance and HIV infection is not consistent across settings (although the available data are limited to a few countries). In addition, HIV status is unknown for large proportions of patients in these cohorts. Countries are still experiencing great difficulties in incorporating HIV testing in drug resistance surveys, as this requires strong collaboration between HIV and TB control programmes. Understanding the relationship between HIV infection and drug-resistant TB at the population level is critical to identify high-risk groups in need of additional support.

Trend analysis suggests that MDR-TB can be controlled once bold policy decisions are put into practice and the correct prevention and control measures are implemented. This is illustrated by recent findings reported from selected oblasts in the Russian Federation, where MDR-TB has been recognized as a serious problem since the time of the dissolution of the Soviet Union. In Arkhangelsk, Tomsk and Orel oblasts, TB case notifications are stable or decreasing, and although MDR-TB rates were increasing until 2005–2006, more recent data show a stabilizing (Arkhangelsk) or even declining trend (Tomsk and Orel). These settings, which have been treating many cases with MDR-TB in recent years, show that MDR-TB can be controlled even in places heavily affected by drug resistance. The same can be said for Estonia and Latvia, where TB and MDR-TB have been declining

for more than a decade. In the United States, rates of MDR-TB are falling even more quickly than rates of TB. These last three countries have strong control programmes that have succeeded in reducing both susceptible and resistant forms of TB. In contrast, in the Republic of Korea, TB and MDR-TB notifications are both increasing, the latter more rapidly than the former. The diversity of treatment options and case management in the country, particularly in the large private health sector, may be facilitating the development of drug resistance.³⁵ In Botswana TB notification rates have stabilized, whereas in Peru they have declined, in line with previous assessments.³⁶ However, in both countries MDR-TB notification rates are showing a very marked increase.

Conclusion

Following 15 years of intensive effort, high-quality surveillance data on anti-TB drug resistance are available for two thirds of all countries in the world. These data show where MDR-TB rates are highest and demonstrate that in selected settings a proper response can alleviate the problem. At the same time, global trends in rates of MDR-TB remain unclear, largely because national representative data are lacking in many large countries, including India and several African countries. A better understanding of epidemiological trends in drug resistance at the global and national levels can be achieved only through repeated surveys and, ultimately, by establishing continuous surveillance based on routine drug susceptibility testing of all confirmed TB cases, with priority given to previously treated patients. Special studies are also needed to help us better understand the factors conducive to the development and spread of MDR-TB. If properly and intensively implemented and followed by appropriate treatment of all TB patients, new technologies can accelerate the response to the threat of drug resistance, save lives and reduce the burden TB imposes on individuals, households and communities. ■

Competing interests: None declared.

ملخص

مراقبة مقاومة الأدوية المضادة للسل في العالم: تحليل محدث، 2010-2007

3.4% (معامل الثقة 95٪، معامل الثقة: 1.9–5.0) من جميع حالات السل الجديدة وفي 19.8% (معامل الثقة 95٪، معامل الثقة: 14.4–25.1) من حالات السل التي سبق علاجها. ولم يتم العثور على ارتباطات عامة بين السل المقاوم للأدوية المتعددة (MDR-TB) وعدوى فيروس نقص المناعة البشرية (HIV) (نسبة الاحتمال، نسبة الاحتمال: 1.4، معامل الثقة 95٪، معامل الثقة: 0.7–3.0) أو الجنس (نسبة الاحتمال، نسبة الاحتمال: 1.1، معامل الثقة 95٪، معامل الثقة: 0.8–1.4). وفيما بين عامي 1994 و2010، زادت معدلات السل المقاوم للأدوية المتعددة (MDR-TB) في عامة السكان في بوتسوانا وجمهورية كوريا وبيرو وانخفضت في إستونيا ولا تفتيا والولايات المتحدة الأمريكية. الاستنتاج فيما بين عامي 2009 و2010 تم توثيق أعلى المعدلات العالمية للسل المقاوم للأدوية المتعددة (MDR-TB) التي تم الإبلاغ عنها. ولا تزال الاتجاهات في السل المقاوم للأدوية المتعددة (MDR-TB) غير واضحة في معظم البيئات. ويلزم وجود مراقبة أو بيانات مسوح أفضل، خاصة من أفريقيا والهند.

الغرض تقديم تحديث عالمي للسل المقاوم للأدوية واستكشاف الاتجاهات فيما بين 1994 و2010.

الطريقة تم تحليل البيانات الخاصة بمقاومة الأدوية بين مرضى السل الجدد والذين سبق علاجهم وفق التقارير المرفوعة من البلدان إلى منظمة الصحة العالمية. وتم تجميع هذه البيانات من خلال مسح تمثيلية للمرضى أو نظم المراقبة بناءً على الاختبار الروتيني للحساسية الدوائية. وتم استكشاف الارتباطات بين السل المقاوم للأدوية المتعددة (MDR-TB) وعدوى فيروس نقص المناعة البشرية (HIV) والجنس من خلال الارتداد اللوجستي.

النتائج فيما بين عامي 2007 و2010، أبلغت 80 بلداً و8 أقاليم عن بيانات المراقبة. وكانت معدلات السل المقاوم للأدوية المتعددة بين الحالات الجديدة، والتي سبق علاجها أعلى في الاتحاد الروسي (مورمانسك أوبلاست، 28.9٪) وجمهورية مولدوفا (65.1٪)، على التوالي. وكانت نسبة أكثر من 10٪ من حالات السل المقاوم للأدوية المتعددة شديدة المقاومة للأدوية في ثلاثة من بلدان الاتحاد السوفيتي السابق وجنوب أفريقيا. وعلى الصعيد العالمي، لوحظت مقاومة للأدوية المتعددة في الفترة ما بين عامي 1994 و2010 في

摘要

抗结核药药物抗药性全球监测：分析更新，2007–2010

目的 介绍抗药性结核病 (TB) 的全球更新并探索 1994 年至 2010 年的趋势。

方法 分析由各个国家向世界卫生组织报告的初诊和复诊 TB 病人的抗药性数据。这些数据是通过基于例行药物敏感性测试的典型病人调查或监测系统收集而来。使用逻辑回归分析研究耐多药 TB (MDR-TB) 与人类免疫缺陷病毒 (HIV) 感染和性行为之间的关联。

结果 在 2007 年至 2010 年期间有 80 个国家及 8 个地区报告监测数据。初诊和复诊病例中 MDR-TB 比率最高的分别是俄罗斯联邦 (摩尔曼斯克州，28.9%) 和摩尔多瓦共和国 (65.1%)。三个前苏联国家和南非有超过 10% 的 MDR-TB 病例是广泛抗药性结核病。1994 年至

2010 年期间全球所有初诊 TB 病例中有 3.4% (95% 置信区间，CI: 1.9–5.0) 的病例观察到耐多药结核病，在复诊 TB 病例中有 19.8% (95% CI: 14.4–25.1) 的病例观察到耐多药结核病。未发现 MDR-TB 与 HIV 感染 (优势比，OR: 1.4; 95% CI: 0.7–3.0) 或性行为 (OR: 1.1; 95% CI: 0.8–1.4) 之间的整体性关联。在 1994 年至 2010 年期间，博茨瓦纳、韩国和秘鲁一般大众的 MDR-TB 率升高，而爱沙尼亚、拉脱维亚和美国的 MDR-TB 率则降低。

结论 2009 年和 2010 年出现了有报告以来的全球最高 MDR-TB 率。在多数环境中 MDR-TB 趋势依旧不明。需要更好的监测或调查数据，尤其是非洲和印度的数据。

Résumé

Surveillance de la résistance aux médicaments antituberculeux dans le monde: une analyse actualisée, 2007-2010

Objectif Présenter une mise à jour globale de la tuberculose (TB) pharmacorésistante et explorer les tendances de 1994 à 2010.

Méthodes Les données relatives à la résistance aux médicaments des nouveaux patients de TB et de ceux traités antérieurement, telles que rapportées par les pays à l'Organisation mondiale de la Santé, ont été analysées. Ces données sont recueillies par des enquêtes représentatives auprès des patients ou des systèmes de surveillance basés sur des tests systématiques de sensibilité. Les associations entre la tuberculose ultra-résistante (TB-UR), le virus de l'immunodéficience humaine (VIH) et le sexe ont été explorées par régression logistique.

Résultats En 2007–2010, 80 pays et 8 territoires ont fourni des données de surveillance. Parmi les cas nouveaux et traités antérieurement, la TB-UR était la plus élevée dans la Fédération de Russie (oblast de Mourmansk, 28,9%) et la République de Moldavie (65,1%), respectivement. Dans trois pays de l'ex-Union soviétique et en Afrique du Sud, plus de 10%

des cas de TB-UR étaient ultra-résistants. Globalement, en 1994–2010, la multirésistance aux médicaments a été observée chez 3,4% (intervalle de confiance 95%, IC: 1,9 à 5,0) de tous les nouveaux cas de TB et 19,8% (IC 95%: 14,4 à 25,1) des cas de TB traités antérieurement. Aucune association générale entre la TB-UR et l'infection au VIH (rapports de cotes, OR: 1,4, IC 95%: 0,7 à 3,0) ou le sexe (OR: 1,1, IC 95%: 0,8 à 1,4) n'a été trouvée. Entre 1994 et 2010, les taux de TB-UR dans la population générale ont augmenté au Botswana, en République de Corée et au Pérou et diminué en Estonie, Lettonie et aux États-Unis d'Amérique.

Conclusion Les taux mondiaux les plus élevés jamais signalés de TB-UR ont été documentés en 2009 et 2010. Les tendances de la TB-UR sont encore peu claires dans la plupart des paramètres. De meilleures données de surveillance ou d'enquête sont nécessaires, surtout en provenance d'Afrique et d'Inde.

Резюме

Обзор устойчивости к воздействию противотуберкулезных препаратов в мире: новейший анализ, 2007–2010 гг.

Цель Представить новейший глобальный анализ лекарственно-устойчивого туберкулеза (ТБ) и исследовать тенденции в период с 1994 по 2010 гг.

Методы Были проанализированы данные об устойчивости к лекарственным препаратам среди новых и уже проходивших лечение от туберкулеза пациентов, полученные на основе докладов стран, направленных во Всемирную Организацию Здравоохранения. Эти данные были собраны посредством репрезентативных обследований пациентов или же с использованием систем мониторинга, основанных на обычном тестировании лекарственной устойчивости. Посредством логистической регрессии были исследованы связи между полирезистентным туберкулезом (MDR-TB), вирусом иммунодефицита человека (HIV) и полом.

Результаты В 2007–2010 гг. 80 стран и 8 территорий предоставили данные, полученные на основе проведенного мониторинга. Количество случаев полирезистентного туберкулеза среди новых или уже проходивших лечение от туберкулеза пациентов было самым высоким в Российской Федерации (Мурманская область, 28,9%) и Республике Молдова (65,1%), соответственно. В трех бывших республиках Советского Союза и Южной

Африке более 10% случаев полирезистентного туберкулеза в основном являлись устойчивыми к воздействию медицинских препаратов. В мире, в период с 1994 по 2010 гг., лекарственная устойчивость наблюдалась в 3,4% (95% доверительный интервал, ДИ: 1,9–5,0) всех новых случаев заболевания туберкулезом и у 19,8% (95% доверительный интервал, ДИ: 14,4–25,1) пациентов, уже проходивших лечение от туберкулеза. Не было обнаружено каких-либо общих связей между полирезистентным туберкулезом, вирусом иммунодефицита человека (отношение рисков, ОР: 1,4; 95% ДИ: 0,7–3,0) или полом (ОР: 1,1; 95% ДИ: 0,8–1,4). В период с 1994 по 2010 гг. темпы заболеваемости полирезистентным туберкулезом среди населения в целом увеличились в Ботсване, Республике Корея и Перу и снизились в Эстонии, Латвии и Соединенных Штатах Америки

Вывод Самый высокий глобальный уровень заболеваемости полирезистентным туберкулезом из когда-либо зарегистрированных был отмечен в 2009 и 2010 гг. По большинству параметров тенденции в отношении полирезистентного туберкулеза остаются неясными. Необходимо улучшить систему мониторинга и сбора данных, в особенности в Африке и Индии.

Resumen

Vigilancia de la resistencia a los medicamentos contra la tuberculosis en todo el mundo: análisis actualizado, 2007–2010

Objetivo Presentar una actualización global de la situación de la tuberculosis (TB) resistente a los medicamentos y analizar las tendencias entre 1994 y 2010.

Método Se analizaron los datos sobre la resistencia a los medicamentos entre los pacientes recién diagnosticados con TB y los que habían recibido tratamiento con anterioridad, en base a los informes que los países remitieron a la Organización Mundial de la Salud. Dichos datos se recopilaron a través de encuestas representativas a pacientes o mediante sistemas de vigilancia basados en pruebas rutinarias de sensibilidad a los medicamentos. A través de una regresión logística se analizaron las asociaciones existentes entre la tuberculosis multirresistente (TB-MDR), el virus de la inmunodeficiencia humana y el sexo.

Resultados Entre 2007 y 2010, 80 países y 8 territorios facilitaron sus datos de vigilancia. Los niveles más elevados de TB-MDR entre los casos recién diagnosticados y previamente tratados se registraron en la Federación de Rusia (Murmansk oblast, 28,9%) y la República de Moldova (65,1%), respectivamente. En tres de los países de la antigua

Unión Soviética y en Sudáfrica, más de un 10% de los casos de TB-MDR fueron extremadamente resistentes. Entre 1994 y 2010 se observó en todo el mundo una multirresistencia de un 3,4% (95% de intervalo de confianza, IC: 1,9–5,0) en todos los casos nuevos de TB y de un 19,8% (95% IC: 14,4–25,1) en los casos de TB previamente tratados. No se observaron asociaciones globales entre la TB-MDR y la infección por el VIH (cociente de posibilidades, OR: 1,4; IC del 95%: 0,7–3,0) ni con el sexo (OR: 1,1; IC del 95%: 0,8–1,4). Entre los años 1994 y 2010, las tasas de TB-MDR en la población general aumentaron en Botswana, la República de Corea y Perú y descendieron en Estonia, Letonia y Estados Unidos de América.

Conclusión En 2009 y 2010 se registraron las tasas globales de MDR-TB más altas de la historia. Las tendencias de TB-MDR siguen sin quedar claras en la mayoría de los entornos. Es necesaria una mejor vigilancia o más datos procedentes de encuestas, especialmente en los casos de África e India.

References

- Cohn DL, Bustreo F, Raviglione MC. Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. International Union Against Tuberculosis and Lung Disease. *Clin Infect Dis* 1997;24(Suppl 1):S121–30. doi:10.1093/clinids/24.Supplement_1.S121 PMID:8994791
- Anti-tuberculosis drug resistance in the world: the WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Geneva: World Health Organization; 1997 (WHO/TB/97.229).
- Pablos-Méndez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F et al. Global surveillance for antituberculosis-drug resistance, 1994–1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. *N Engl J Med* 1998;338:1641–9. PMID:9614254
- Anti-tuberculosis drug resistance in the world: the WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Report 2: Prevalence and trends. Geneva: World Health Organization; 2000 (WHO/CDS/TB/2000.278).
- Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A et al. Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. *N Engl J Med* 2001;344:1294–303. doi:10.1056/NEJM200104263441706 PMID:11320389
- Anti-tuberculosis drug resistance in the world: the WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Third global report. Geneva: World Health Organization; 2004 (WHO/HTM/TB/2004.343).

7. Aziz MA, Wright A, Laszlo A, De Muynck A, Portaels F, Van Deun A et al.; WHO/International Union Against Tuberculosis And Lung Disease Global Project on Anti-tuberculosis Drug Resistance Surveillance. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. *Lancet* 2006;368:2142–54. doi:10.1016/S0140-6736(06)69863-2 PMID:17174706
8. World Health Organization. *Anti-tuberculosis drug resistance in the world: the WHO/UATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Fourth global report*. Geneva, Switzerland: WHO, 2008 (WHO/HTM/TB/2008.394).
9. Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, Feldman K et al.; Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Epidemiology of antituberculosis drug resistance 2002–07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. *Lancet* 2009;373:1861–73. doi:10.1016/S0140-6736(09)60331-7 PMID:19375159
10. *Multidrug and extensively drug-resistant TB (M/XDR-TB):2010 global report on surveillance and response*. Geneva: World Health Organization; 2010.
11. *Global tuberculosis control*. Geneva: World Health Organization; 2011 (WHO/HTM/TB/2011.16).
12. *Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015*. Geneva: World Health Organization; 2011 (WHO/HTM/TB/2011.3).
13. *Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: emergency update*. Geneva: World Health Organization; 2008 (WHO/HTM/TB/2008.402; ISBN 978-92-4-154758-1).
14. *Guidelines for the programmatic management of drug-resistant tuberculosis. 2011 update*. Geneva: World Health Organization; 2011 (WHO/HTM/TB/2011.6).
15. Falzon D, Jaramillo E, Schünemann H, Arentz M, Bayona J, Blanc L et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. *Eur Respir J* 2011;38:516–28. doi:10.1183/09031936.00073611 PMID:21828024
16. *WHO policy on TB infection control in health-care facilities, congregate settings and households*. Geneva: World Health Organization; 2009 (WHO/HTM/TB/2009.419).
17. *Green Light Committee Initiative of the Working Group on MDR-TB of the STOP TB Partnership. Annual report 2009*. Geneva: World Health Organization; 2010 (WHO/HTM/TB/2010.14).
18. *Guidelines for surveillance of drug resistance in tuberculosis*. Fourth edn. Geneva: World Health Organization; 2009 (WHO/HTM/TB/2009.422).
19. Zignol M, van Gemert W, Falzon D, Jaramillo E, Blanc L, Raviglione M. Modernizing surveillance of anti-tuberculosis drug resistance: from special surveys to routine testing. *Clin Infect Dis* 2011;52:901–6. doi:10.1093/cid/cir081 PMID:21427397
20. *The Global Plan to Stop TB 2011–2015*. Geneva: Stop TB Partnership & World Health Organization; 2010.
21. *Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB): policy statement*. Geneva: World Health Organization; 2009. Available from: http://www.who.int/tb/features_archive/policy_statement.pdf. [accessed 28 October 2011]
22. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F et al. Rapid molecular detection of tuberculosis and rifampin resistance. *N Engl J Med* 2010;363:1005–15. doi:10.1056/NEJMoa0907847 PMID:20825313
23. Aziz MA, Wright A. The World Health Organization/International Union Against Tuberculosis and Lung Disease Global Project on Surveillance for Anti-Tuberculosis Drug Resistance: a model for other infectious diseases. *Clin Infect Dis* 2005;41(Suppl 4):S258–62. doi:10.1086/430786 PMID:16032561
24. Van Deun A, Wright A, Zignol M, Weyer K, Rieder HL. Drug susceptibility testing proficiency in the network of supranational tuberculosis reference laboratories. *Int J Tuberc Lung Dis* 2011;15:116–24. PMID:21276307
25. *Treatment of tuberculosis guidelines*. Fourth ed. Geneva: World Health Organization; 2009 (WHO/HTM/TB/2009.420).
26. The WHO global data collection system [Internet]. Geneva: World Health Organization; 2011. Available from: <http://www.stoptb.org/tme/> [accessed 28 October 2011]
27. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557–60. doi:10.1136/bmj.327.7414.557 PMID:12958120
28. United Nations. [database]. Population. New York: Department of Economic and Social Affairs, Population Division. Available from: <http://esa.un.org/unpd/wpp/unpp/> [accessed August 2011]
29. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. *Lancet* 2006;368:1575–80. doi:10.1016/S0140-6736(06)69573-1 PMID:17084757
30. Rigouts L, Hoza AS, De Rijk P, Torrea G, Chonde TM, Basra D et al. Evaluation of the Genotype® MTBDRplus assay as a tool for drug-resistance surveys. *Int J Tuberc Lung Dis* 2011;15:959–65. doi:10.5588/ijtld.10.0515 PMID:21682972
31. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. *Am J Respir Crit Care Med* 2008;177:787–92. doi:10.1164/rccm.200709-1436OC PMID:18202343
32. Edlin BR, Tokars JI, Grieco MH, Crawford JT, Williams J, Sordillo EM et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. *N Engl J Med* 1992;326:1514–21. doi:10.1056/NEJM199206043262302 PMID:1304721
33. Moro ML, Gori A, Errante I, Infuso A, Franzetti F, Sodano L et al. An outbreak of multidrug-resistant tuberculosis involving HIV-infected patients of two hospitals in Milan, Italy. Italian Multidrug-Resistant Tuberculosis Outbreak Study Group. *AIDS* 1998;12:1095–102. doi:10.1097/00002030-199809000-00018 PMID:9662207
34. Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A et al. HIV infection and multidrug-resistant tuberculosis: the perfect storm. *J Infect Dis* 2007;196(Suppl 1):S86–107. doi:10.1086/518665 PMID:17624830
35. Seung KJ, Bai GH, Kim SJ, Lew WJ, Park SK, Kim JY. The treatment of tuberculosis in South Korea. *Int J Tuberc Lung Dis* 2003;7:912–9. PMID:14552560
36. Suárez PG, Watt CJ, Alarcón E, Portocarrero J, Zavala D, Canales R et al. The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. *J Infect Dis* 2001;184:473–8. doi:10.1086/322777 PMID:11471105

Table 1. Countries and territories reporting data^a on multidrug resistant tuberculosis (MDR-TB), 2007–2010

Country or setting	Source	Year	New cases				Previously treated cases			
			Cases with DST results (for H & R)	MDR-TB (%)	Resistance (%)		Cases with DST results (for H & R)	MDR-TB (%)	Resistance (%)	
					H	R			H	R
Albania	Surveillance	2010	186	0.5	3.2	0.5	19	5.3	31.6	–
Andorra	Surveillance	2010	4	0.0	25.0	0.0	0	–	–	–
Australia	Surveillance	2010	868	2.4	8.9	2.6	48	22.9	29.2	–
Austria	Surveillance	2010	240	2.1	8.8	2.1	16	18.8	18.8	–
Bahamas	Surveillance	2010	21	0.0	0.0	23.8	2	0.0	0.0	–
Bahrain	Surveillance	2010	162	0.0	0.0	0.0	0	–	–	–
Bangladesh (14 districts covering 30 million population)	Surveillance	2008	–	–	–	–	599	28.0	37.6	–
Belarus	Surveillance	2010	1972	25.7	33.2	27.2	1697	60.2	66.7	–
Belgium	Surveillance	2009	621	0.6	3.9	0.8	56	5.4	10.7	–
Benin	Survey	2010	403	0.5	7.9	1.2	45	13.3	31.1	–
Bermuda	Surveillance	2010	1	0.0	0.0	0.0	0	–	–	–
Bolivia (Plurinational State of)	Surveillance	2010	–	–	–	–	664	16.0	24.4	16.6
Bosnia and Herzegovina	Surveillance	2009	854	0.0	0.6	0.0	66	3.0	12.1	3.0
Botswana	Survey	2008	924	2.5	7.6	3.6	137	6.6	10.3	13.2
Brunei Darussalam	Surveillance	2010	181	0.0	2.8	0.0	5	0.0	0.0	0.0
Bulgaria	Surveillance	2010	801	2.0	6.6	2.9	165	24.2	35.1	28.4
Cambodia	Survey	2007	781	1.4	7.2	1.8	56	10.7	17.8	10.7
Canada	Surveillance	2010	987	1.5	8.2	1.5	51	0.0	9.8	0.0
Central African Republic, Bangui and Bimbo	Survey	2009	225	0.4	9.3	0.4	–	–	–	–
Chile	Surveillance	2010	–	–	–	–	276	2.9	13.4	7.2
China	Survey	2007	3037	5.7	15.9	6.6	892	25.6	38.8	29.7
China, Hong Kong Special Administrative Region	Surveillance	2009	2056	0.7	4.6	1.0	234	2.6	7.7	2.6
China, Macao Special Administrative Region	Surveillance	2010	221	1.8	6.3	2.2	39	5.1	10.2	5.1
Colombia	Surveillance	2010	–	–	–	–	495	15.8	25.5	17.0
Curaçao	Surveillance	2010	5	0.0	40.0	0.0	0	–	–	–
Cyprus	Surveillance	2009	27	14.8	22.2	14.8	4	0.0	–	–
Czech Republic	Surveillance	2009	413	1.2	2.9	1.9	39	7.7	10.3	7.7
Denmark	Surveillance	2009	209	0.5	6.7	0.5	33	3.0	12.1	3.0
El Salvador	Surveillance	2009	–	–	–	–	85	1.2	5.9	1.2
Estonia	Surveillance	2010	197	18.3	25.9	18.8	61	44.3	50.9	44.3
Fiji	Surveillance	2009	–	–	–	–	2	0.0	0.0	0.0
Finland	Surveillance	2010	239	2.1	6.7	2.5	3	12.5	12.5	12.5
France	Surveillance	2009	1304	1.0	2.7	1.1	106	13.2	17.0	14.2
French Polynesia	Surveillance	2009	42	0.0	0.0	0.0	4	0.0	0.0	0.0
Georgia	Surveillance	2010	1987	9.5	23.1	9.9	558	30.6	44.0	31.1
Germany	Surveillance	2010	2138	1.3	7.1	1.6	130	6.2	15.4	7.7
Greece	Surveillance	2009	140	6.4	11.4	6.4	14	28.6	50.0	35.7
Guam	Surveillance	2010	56	3.6	10.7	3.6	2	0.0	0.0	0.0
Hungary	Surveillance	2009	486	3.3	8.4	3.7	55	7.3	18.2	7.3
Iceland	Surveillance	2010	19	0.0	31.6	0.0	0	–	–	–
Indonesia, Central Java province	Survey	2006	1126	1.8	11.4	2.1	70	17.1	24.2	21.7
Ireland	Surveillance	2010	176	1.1	5.1	2.2	21	0.0	4.8	0.0
Israel	Surveillance	2010	245	4.9	11.4	7.3	2	0.0	50.0	0.0
Italy	Surveillance	2009	1051	3.2	8.4	3.8	264	12.5	21.2	13.7

Country or setting	Source	Year	New cases				Previously treated cases			
			Cases with DST results (for H & R)	MDR-TB (%)	Resistance (%)		Cases with DST results (for H & R)	MDR-TB (%)	Resistance (%)	
					H	R			H	R
Jordan	Surveillance	2009	95	6.3	9.5	6.3	7	28.6	28.6	28.6
Kazakhstan	Surveillance	2010	–	–	–	–	4655	45.1	58.8	48.3
Kuwait	Surveillance	2010	437	1.1	10.0	1.3	0	–	–	–
Latvia	Surveillance	2010	613	10.3	25.8	10.3	102	23.5	39.2	23.5
Lebanon	Surveillance	2010	–	–	–	–	14	35.7	35.7	35.7
Lithuania	Surveillance	2009	1074	10.6	21.4	11.1	404	51.5	61.6	52.2
Luxembourg	Surveillance	2009	27	0.0	11.1	0.0	–	–	–	–
Madagascar	Survey	2007	810	0.5	4.6	0.5	51	3.9	9.8	5.9
Malta	Surveillance	2009	17	0.0	5.9	0.0	0	–	–	–
Marshall Islands	Surveillance	2010	68	1.5	3.0	1.5	3	0.0	0.0	0.0
Mauritius	Surveillance	2010	105	1.0	2.9	1.0	7	14.3	14.3	14.3
Mexico	Survey	2009	1584	2.4	8.5	2.6	191	6.5	15.5	10.9
Mongolia	Surveillance	2010	–	–	–	–	561	30.1	36.5	30.8
Mongolia	Survey	2007	650	1.4	12.6	2.2	–	–	–	–
Montenegro	Surveillance	2010	61	0.0	4.9	0.0	12	0.0	0.0	0.0
Mozambique	Survey	2007	1102	3.5	7.8	3.7	25	11.2	15.2	19.6
Myanmar	Survey	2008	1071	4.2	5.2	4.9	299	10.0	11.7	10.7
Namibia	Survey	2008	1054	3.8	13.5	4.6	354	16.4	38.4	22.0
Netherlands	Surveillance	2010	741	1.3	8.5	1.4	29	3.4	13.7	3.4
New Zealand	Surveillance	2009	237	2.5	9.3	2.5	8	12.5	12.5	12.5
Northern Mariana Islands	Surveillance	2010	17	0.0	5.9	0.0	0	–	–	–
Norway	Surveillance	2009	210	3.8	9.0	4.3	20	0.0	10.0	0.0
Oman	Surveillance	2010	185	0.0	8.1	0.5	8	12.5	12.5	12.5
Palau	Surveillance	2010	11	0.0	0.0	0.0	0	–	–	–
Paraguay	Survey	2008	319	0.3	1.9	0.9	48	14.6	16.7	14.6
Poland	Surveillance	2008	3758	0.5	3.1	0.5	607	5.6	9.7	5.9
Portugal	Surveillance	2009	1391	0.9	6.8	1.0	148	6.1	8.8	6.1
Puerto Rico	Surveillance	2010	69	0.0	10.1	0.0	4	0.0	0.0	0.0
Qatar	Surveillance	2010	324	1.2	5.8	1.2	0	–	–	–
Republic of Moldova	Surveillance	2010	–	–	–	–	1077	65.1	74.0	66.4
Russian Federation, Arkhangelsk oblast	Surveillance	2009 ^b	292	25.7	–	–	68	58.8	–	–
Russian Federation, Belgorod oblast	Surveillance	2009 ^b	358	19.8	–	–	91	51.6	–	–
Russian Federation, Bryansk oblast	Surveillance	2009 ^b	560	11.1	–	–	54	27.8	–	–
Russian Federation, Ivanovo oblast	Surveillance	2009 ^b	276	20.3	–	–	52	57.7	–	–
Russian Federation, Kaliningrad oblast	Surveillance	2009 ^b	354	22.3	–	–	51	43.1	–	–
Russian Federation, Mary El Republic	Surveillance	2009 ^b	366	15.6	–	–	53	37.7	–	–
Russian Federation, Murmansk oblast	Surveillance	2009 ^b	190	28.9	–	–	14	35.7	–	–
Russian Federation, Orel oblast	Surveillance	2009 ^b	256	6.3	–	–	29	48.3	–	–
Russian Federation, Pskov oblast	Surveillance	2009 ^b	304	24.3	–	–	44	50.0	–	–
Russian Federation, Republic of Chuvashia	Surveillance	2009 ^b	579	15.2	–	–	92	45.7	–	–
Russian Federation, Tomsk oblast	Surveillance	2009 ^b	435	11.3	–	–	80	53.8	–	–
Russian Federation, Vladimir oblast	Surveillance	2009 ^b	422	20.9	–	–	55	32.7	–	–

Country or setting	Source	Year	New cases				Previously treated cases			
			Cases with DST results (for H & R)	MDR-TB (%)	Resistance (%)		Cases with DST results (for H & R)	MDR-TB (%)	Resistance (%)	
					H	R			H	R
Rwanda	Surveillance	2010	–	–	–	–	431	19.0	20.2	21.3
Serbia	Surveillance	2008	923	0.7	2.0	0.7	130	7.7	12.3	7.7
Singapore	Surveillance	2010	923	0.2	2.3	0.3	79	1.3	6.4	2.6
Slovakia	Surveillance	2010	185	0.0	2.7	0.0	32	3.1	9.4	3.1
Slovenia	Surveillance	2009	167	0.5	2.4	0.6	8	0.0	0.0	0.0
Sri Lanka	Surveillance	2010	–	–	–	–	378	1.6	5.3	2.6
Swaziland	Survey	2009	352	7.7	13.4	8.0	231	33.9	45.3	36.4
Sweden	Surveillance	2010	440	2.5	9.1	3.0	30	23.3	40.0	23.3
Switzerland	Surveillance	2010	270	0.4	2	0.4	33	9.1	33.3	12.1
Tajikistan, Dushanbe city and Rudaki district	Survey	2009	139	16.5	26.6	16.6	125	61.6	74.4	64.8
Former Yugoslav Republic of Macedonia	Surveillance	2010	153	1.3	3.9	1.3	28	17.9	17.9	17.9
Uganda, Kampala	Survey	2008	473	1.1	5.8	1.5	60	11.7	20.0	13.4
United Kingdom of Great Britain and Northern Ireland	Surveillance	2009	3957	0.9	6.6	1.1	364	3.3	7.7	4.1
United States of America	Surveillance	2010	6514	1.1	7.5	1.5	293	4.4	16.0	5.8

DST, drug susceptibility testing; H, isoniazid; R, rifampicin.

^a Data from the most recent year are shown.

^b 2009 data for new TB cases and 2008 data for previously treated TB cases.

Note: The data were obtained from the World Health Organization.^{10,11}

Table 2. Countries and territories reporting data^a on extensively drug-resistant tuberculosis (XDR-TB), 2007–2010

Country or territory	Source	Year	No. of cases of MDR-TB	MDR-TB cases with DST results for 2nd-line drugs	No. of cases of XDR-TB (%)
Albania	Surveillance	2010	2	2	0 (0.0)
Australia	Surveillance	2010	32	32	1 (3.1)
Austria	Surveillance	2010	15	15	1 (6.7)
Bangladesh (14 districts covering 30 million population) ^b	Surveillance	2008	168	168	1 (0.6)
Belgium	Surveillance	2009	10	10	3 (30.0)
Botswana	Survey	2008	32	24	0 (0.0)
Bulgaria	Surveillance	2008	32	28	0 (0.0)
Canada	Surveillance	2010	15	14	1 (7.1)
China	Survey	2008	401	401	29 (7.2)
China, Hong Kong Special Administrative Region	Surveillance	2009	3	3	0 (0.0)
China, Macao Special Administrative Region	Surveillance	2010	6	6	0 (0.0)
Cyprus	Surveillance	2008	1	1	0 (0.0)
Czech Republic	Surveillance	2008	11	10	1 (10.0)
Denmark	Surveillance	2007	2	2	0 (0.0)
Estonia	Surveillance	2010	63	61	12 (19.7)
Georgia	Surveillance	2010	359	313	30 (9.6)
Greece	Surveillance	2009	14	9	3 (33.3)
Guam	Surveillance	2010	2	2	0 (0.0)
Iceland	Surveillance	2008	1	1	0 (0.0)
India, Gujarat state	Survey	2006	216	216	7 (3.2)
Israel	Surveillance	2010	12	12	1 (8.3)
Italy	Surveillance	2009	82	32	1 (3.1)
Latvia	Surveillance	2010	87	86	13 (15.1)
Marshall Islands	Surveillance	2010	1	1	0 (0.0)
Montenegro	Surveillance	2009	1	1	0 (0.0)
Namibia	Survey	2008	100	100	0 (0.0)
Norway	Surveillance	2008	4	4	0 (0.0)
Oman	Surveillance	2010	1	1	0 (0.0)
Paraguay	Survey	2008	8	8	0 (0.0)
Poland	Surveillance	2008	52	52	5 (9.6)
Qatar	Surveillance	2010	4	4	0 (0.0)
Singapore	Surveillance	2010	3	3	0 (0.0)
Slovakia	Surveillance	2010	1	1	0 (0.0)
South Africa	Surveillance	2008	8026	5451	572 (10.5)
Swaziland	Survey	2009	122	122	1 (0.8)
Sweden	Surveillance	2009	13	9	0 (0.0)
Switzerland	Surveillance	2010	8	8	0 (0.0)
Tajikistan, Dushanbe city and Rudaki district	Survey	2009	100	100	21 (21.0)
Former Yugoslav Republic of Macedonia	Surveillance	2010	7	5	1 (20.0)
United Kingdom of Great Britain and Northern Ireland	Surveillance	2009	58	40	2 (5.0)
United States of America	Surveillance	2010	92	59	1 (1.7)

DST, drug susceptibility testing; MDR-TB, multidrug resistant tuberculosis.

^a Data from the most recent year are shown.

^b Only previously treated cases.

Note: The data were obtained from the World Health Organization.^{10,11}